248 related articles for article (PubMed ID: 2211567)
21. Buspirone in social phobia.
Schneier FR; Saoud JB; Campeas R; Fallon BA; Hollander E; Coplan J; Liebowitz MR
J Clin Psychopharmacol; 1993 Aug; 13(4):251-6. PubMed ID: 8376612
[TBL] [Abstract][Full Text] [Related]
22. Buspirone: multicenter efficacy study.
Wheatley D
J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):92-4. PubMed ID: 6130079
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
[TBL] [Abstract][Full Text] [Related]
24. Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial.
Meibach RC; Dunner D; Wilson LG; Ishiki D; Dager SR
J Clin Psychiatry; 1987 Sep; 48(9):355-8. PubMed ID: 3305488
[TBL] [Abstract][Full Text] [Related]
25. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder.
Ballenger JC; McDonald S; Noyes R; Rickels K; Sussman N; Woods S; Patin J; Singer J
Psychopharmacol Bull; 1991; 27(2):171-9. PubMed ID: 1681563
[TBL] [Abstract][Full Text] [Related]
26. The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency.
Tollefson GD; Lancaster SP; Montague-Clouse J
Psychopharmacol Bull; 1991; 27(2):163-70. PubMed ID: 1924664
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety.
Sramek JJ; Hong WW; Hamid S; Nape B; Cutler NR
Depress Anxiety; 1999; 9(3):131-4. PubMed ID: 10356651
[TBL] [Abstract][Full Text] [Related]
28. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
Amini H; Aghayan S; Jalili SA; Akhondzadeh S; Yahyazadeh O; Pakravan-Nejad M
J Clin Pharm Ther; 2005 Apr; 30(2):133-8. PubMed ID: 15811165
[TBL] [Abstract][Full Text] [Related]
29. Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety.
Small GW; Bystritsky A
J Clin Psychiatry; 1997; 58 Suppl 11():24-9. PubMed ID: 9363045
[TBL] [Abstract][Full Text] [Related]
30. Buspirone and diazepam in anxiety: a controlled study.
Rickels K; Weisman K; Norstad N; Singer M; Stoltz D; Brown A; Danton J
J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):81-6. PubMed ID: 6130078
[TBL] [Abstract][Full Text] [Related]
31. The safety and usefulness of buspirone as an anxiolytic drug in elderly versus young patients.
Robinson D; Napoliello MJ; Schenk J
Clin Ther; 1988; 10(6):740-6. PubMed ID: 3219687
[TBL] [Abstract][Full Text] [Related]
32. Comparison of buspirone in two separate studies.
Goldberg HL; Finnerty R
J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):87-91. PubMed ID: 6759499
[TBL] [Abstract][Full Text] [Related]
33. [Buspirone in the treatment of Generalized Anxiety Disorders].
Rzewuska M; Sobucka K
Psychiatr Pol; 1993; 27(5):545-61. PubMed ID: 8255947
[TBL] [Abstract][Full Text] [Related]
34. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.
Pollack MH; Tiller J; Xie F; Trivedi MH
J Clin Psychopharmacol; 2008 Jun; 28(3):308-16. PubMed ID: 18480688
[TBL] [Abstract][Full Text] [Related]
35. [Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks].
Kinzler E; Krömer J; Lehmann E
Arzneimittelforschung; 1991 Jun; 41(6):584-8. PubMed ID: 1930344
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders].
Lemoine P; Rouillon F; Pouget D
Encephale; 1996; 22(6):461-7. PubMed ID: 10901839
[TBL] [Abstract][Full Text] [Related]
37. A double-blind cross-over evaluation of the activity of d-oxazepam hemisuccinate sodium salt (D-7-chloro-1,3-dihydro-3-hemisuccinyloxy-5-phenyl-2H-1,4-benzodiazepine-2-one) compared to its racemic form.
Lescovelli M; Castellani A; Perbellini D
Arzneimittelforschung; 1976; 26(8):1623-6. PubMed ID: 795440
[TBL] [Abstract][Full Text] [Related]
38. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study.
Delle Chiaie R; Pancheri P; Casacchia M; Stratta P; Kotzalidis GD; Zibellini M
J Clin Psychopharmacol; 1995 Feb; 15(1):12-9. PubMed ID: 7714222
[TBL] [Abstract][Full Text] [Related]
39. [D,L-kavain in comparison with oxazepam in anxiety disorders. A double-blind study of clinical effectiveness].
Lindenberg D; Pitule-Schödel H
Fortschr Med; 1990 Jan; 108(2):49-50, 53-4. PubMed ID: 2179082
[TBL] [Abstract][Full Text] [Related]
40. Analysis of individual symptoms in generalized anxiety--a pooled, multistudy, double-blind evaluation of buspirone.
Feighner JP; Cohn JB
Neuropsychobiology; 1989; 21(3):124-30. PubMed ID: 2615929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
